The global subcutaneous drug delivery devices market size was valued at USD 21.2 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 10.4% from 2020 to 2027. Availability of advanced minimally invasive drug delivery devices, rising prevalence of diabetes and Cardiovascular Diseases (CVD), and a surge in biologic drug development have driven the demand for subcutaneous self-administrating drug delivery devices. According to the International Diabetes Federation (IDF), the diabetic population is anticipated to grow by 48.0% annually between 2017 and 2045 globally. IDF further stated that diabetes incidence will majorly rise drastically in low and middle-income countries, as compared to the developed countries. Also, as per the World Heart Federation, adults with type 2 diabetes are highly susceptible to develop CVD, as compared to non-diabetics.
Increasing adoption of subcutaneous drug delivery devices has resulted in the reduction in dosage errors and the prevention of needlestick injuries. Higher treatment adherence is observed in patients with devices having easy drug administration protocols. According to the Annals of Internal Medicine, nearly 50.0% of patients with prescriptions for chronic conditions stop taking it within the first year. Moreover, the study also stated that lack of treatment adherence leads to 125,000 deaths, 10.0% hospitalizations, and costs USD 17 billion to the American healthcare system annually. Thus, pain-free subcutaneous drug delivery devices can directly have an impact on managing several chronic medical conditions.
The needle-free injectors have emerged as potential alternatives for conventional drug delivery platforms as they eliminate needlestick injuries and reduce associated treatment costs. According to the Occupational Safety and Health Administration, 384,000 needlestick injuries and other sharps-related injuries are reported in the healthcare personnel in the U.S. annually. According to the survey conducted by PATH Vaccine Resource Library, 21.0 million hepatitis B, 260,000 HIV, and 2 million hepatitis C infections are registered from needlestick injuries, leading to 1.3 million early deaths globally.
The pen injectors segment dominated the market for subcutaneous drug delivery devices and accounted for the largest revenue share of 38.0% in 2019. Increasing product approvals, easy product design, affordability, and greater social acceptance are positive growth indicators. The developers are engaged in addressing the shortcomings of these delivery devices to gain a competitive edge in the market for subcutaneous drug delivery devices. For instance, in March 2018, Sanofi S.A. announced the U.S. FDA approval for its maximum unit injection pen - Toujeo Max SoloStar. The device is designed to accommodate a volume of 900 units/mL. The device will help in reducing injection numbers and thus lower medical spending.
The wearable injectors segment is expected to register the highest growth rate in the subcutaneous drug delivery devices market over the forecast period. The wearable injectors, also called patch pumps or bolus injectors are increasingly prescribed by physicians to administer high-viscosity and large-volume biologic drugs. These digitally powered subcutaneous drug delivery devices can help the physicians to improve the quality of care, thereby reducing total healthcare costs by improving patient outcomes.
The retail pharmacies segment accounted for the largest revenue share of 44.9% in 2019 in the market for subcutaneous drug delivery devices. This can be attributable to factors such as increasing self-administration, patient awareness, and increasing focus on positive medical outcomes. Also, manufacturers are launching programs to enable uninterrupted access to insulin for uninsured patients, thus helping patients amid the COVID crisis.
The online pharmacies segment is expected to showcase the fastest growth rate due to discounts offered by the developers for various subcutaneous drug delivery devices. For instance, in 2017, Eli Lilly partnered with Express Scripts to offer discounts for their products for mobile and web platforms. Thus, the cost-effectiveness of vital medications enables greater access to patients in underdeveloped and developing countries.
North America dominated the market for subcutaneous drug delivery devices and accounted for the largest revenue share of 44.1% in 2019. The region is expected to continue its dominance over the forecast period. This dominance is attributed to developed healthcare infrastructure, local presence of major players, and continuous strategic initiatives implemented to maintain their market share. In December 2019, Portal Instruments, Inc. collaborated with LEO Pharma for the development of a needle-free subcutaneous drug delivery device. Moreover, the increasing prevalence of chronic disease conditions such as multiple sclerosis, cardiovascular diseases, diabetes, and arthritis contribute majorly to the growth of the market for subcutaneous drug delivery devices. According to the National Multiple Sclerosis Society, an estimated 1.0 million adults were reported to be living with multiple sclerosis in the U.S. in 2017.
In Asia Pacific, the market for subcutaneous drug delivery devices is expected to grow at a lucrative rate over the forecast period. The high growth rate in the region is primarily attributed to the rise in diabetic patients. According to the International Diabetes Federation (IDF), Asia comprises 60.0% of the global diabetic population. IDF further stated that India is predicted to have the highest growth rate in terms of diabetics by 2025, with 72.0 million cases recorded in 2017.
The market for subcutaneous drug delivery devices is highly fragmented with the presence of various large and medium-scale vendors offering a variety of subcutaneous drug delivery devices indicated for different disease conditions. Product launch, strategic acquisitions, and product innovation are the major strategies adopted by the market players to retain their market share. In June 2018, Insulet Corporation received the U.S. FDA approval for the Omnipod DASH insulin management system. These digital platforms enable better patient outcomes in diabetic patients. Some of the prominent players in the subcutaneous drug delivery devices market include:
Gerresheimer AG
Medtronic Plc
Ypsomed AG
Elcam Medical Group
Novo Nordisk
Insulet Corporation
Becton, Dickinson and Company
West Pharmaceutical Services, Inc.
PharmaJet
Unilife Corporation
Inolife Sciences
Report Attribute |
Details |
Market size value in 2020 |
USD 23.3 billion |
Revenue forecast in 2027 |
USD 46.6 billion |
Growth Rate |
CAGR of 10.4% from 2020 to 2027 |
Base year for estimation |
2019 |
Historical data |
2016 - 2018 |
Forecast period |
2020 - 2027 |
Quantitative units |
Revenue in USD million and CAGR from 2020 to 2027 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered |
Product, distribution channel, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
The U.S., Canada; The U.K.; Germany; France; Italy; Spain; Japan; China; India; South Korea; Australia; Brazil; Mexico; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Gerresheimer AG; Medtronic Plc; Ypsomed AG; Elcam Medical Group; Novo Nordisk; Insulet Corporation; Becton, Dickinson and Company; West Pharmaceutical Services, Inc.; PharmaJet; Unilife Corporation; Inolife Sciences |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global subcutaneous drug delivery devices market report based on product, distribution channel, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Prefilled syringes
Pen injectors
Auto-injectors
Wearable injectors
Needle-free Injectors
Distribution Channel Outlook (Revenue, USD Million, 2016 - 2027)
Hospital pharmacies
Retail pharmacies
Online pharmacies
Regional Outlook (Revenue, USD Million, 2016 - 2027)
North America
The U.S.
Canada
Europe
The U.K
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global subcutaneous drug delivery devices market is estimated to be valued at USD 21,216.0 million in 2019 and is expected to reach USD 23,308.3 million in 2020.
b. The global subcutaneous drug delivery devices market is expected to grow at a compound annual growth rate of 10.4% from 2020 to 2027 to reach USD 46,622.3 million by 2027.
b. North America dominated the subcutaneous drug delivery devices market with a share of 44.1% in 2019. This is attributable to developed healthcare infrastructure, local presence of major players, and continuous strategic initiatives implemented to maintain their market share.
b. Some key players present operating in the subcutaneous drug delivery devices market include Gerresheimer AG, Medtronic Plc, Novo Nordisk, Ypsomed AG, Becton, Dickinson and Company, Elcam Medical Group, Insulet Corporation, West Pharmaceutical Services, Inc., PharmaJet, Inolife Sciences, and Unilife Corporation.
b. Key factors that are driving the subcutaneous drug delivery devices market growth include the availability of advanced minimally invasive drug delivery systems, rising prevalence of diabetes and cardiovascular diseases (CVD), and the surge in biologic drug development.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.